Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Cefuroxime pharmacokinetics and pharmacodynamics for intravenous dosage regimens with 750 mg or 1500 mg doses in healthy young volunteers

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Comparing DADA2 and OTU clustering approaches in studying the bacterial communities of atopic dermatitis

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Early life bacterial airway colonization, local immune mediator response and risk of otitis media

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Therapeutic drug monitoring of β-lactam antibiotics

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Molecular characterization of Danish ESBL/AmpC-producing Klebsiella pneumoniae from bloodstream infections, 2018

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Exposure of consumers to substandard antibiotics from selected authorised and unauthorised medicine sales outlets in Ghana

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Oral amoxicillin and amoxicillin–clavulanic acid: properties, indications, and usage

    Research output: Contribution to journalReviewResearchpeer-review

  5. Intraindividual variation of the transversus abdominis plane block: an exploratory study in healthy volunteers

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Introduction. Cefuroxime is an important antibiotic to treat several serious infections. Rapid elimination through the kidneys and the variation in MICs of various susceptible pathogens such as Escherichia coli, Klebsiella pneumoniae, Staphylococcus aureus and Streptococcus pneumoniae give rise to dosing issues, especially in otherwise healthy patients. Aim. To investigate the probability of target attainment (PTA) for obtaining the optimal dosage regimens for cefuroxime in healthy young people. Methodology. Two weeks apart 750 and 1500 mg cefuroxime were administered as an intravenous bolus to 20 healthy volunteers (mean age: 27 years). Population modelling and simulation studies were done based on the obtained data for cefuroxime plasma concentration. Results. With a target value of time above MIC (T >MIC) greater than 50% the simulations revealed that a PTA of >99% is obtained for S. pneumoniae with a dosage regimen of 750 mg q12h. For E. coli and K. pneumoniae the PTA was <90% even with the highest, simulated dosage of 1500 mg q6h. For S. aureus a dosage of 1500 mg q8h gave a PTA above 97%. Conclusions. S. pneumoniae is most likely treatable with a two-daily dose of 750 mg cefuroxime. Not treatable are K. pneumoniae and E. coli. For S. aureus 1500 mg q8h constitutes an optimal dosing schedule.

Original languageEnglish
JournalJournal of Medical Microbiology
Volume69
Issue number3
Pages (from-to)387-395
Number of pages9
ISSN0022-2615
DOIs
Publication statusPublished - Mar 2020

    Research areas

  • Breakpoints, Cefuroxime, Healthy volunteers, Pharmacodynamics, Pharmacokinetics, Population modelling, Anti-Bacterial Agents/administration & dosage, Humans, Middle Aged, Klebsiella pneumoniae/drug effects, Male, Healthy Volunteers, Escherichia coli/drug effects, Staphylococcus/drug effects, Cefuroxime/administration & dosage, Staphylococcal Infections/drug therapy, Klebsiella Infections/drug therapy, Microbial Sensitivity Tests, Young Adult, Escherichia coli Infections/drug therapy, Streptococcus pneumoniae/drug effects, Adult, Female, Monte Carlo Method

ID: 59662451